High expression of AXL is associated with lower therapeutic responses and poorer prognosis in ovarian cancer; thus, AXL is a candidate molecule to conquer cisplatin resistance (Kim et al., 2015; Suh et al., 2015; Tian et al., 2021). Here, AXL is linked to ovarian carcinoma.